Drugs / GP-asPNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06451172 | Oct 2023 → Oct 2024 overdue | bacterial infectious disease, blindness (disorder), keratitis | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP-asPNA | “The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.” NCT06451172 ↗ |
| Route | Topical | “Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.” NCT06451172 ↗ |